Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Stock Chart & Stats
$246.61
$3.66(1.38%)
At close: 4:00 PM EST
$246.61
$3.66(1.38%)
Day’s Range― - ―
52-Week Range$230.05 - $354.88
Previous CloseN/A
Volume86.50K
Average Volume (3M)1.09M
Market Cap
$17.36B
Enterprise Value$17.70B
Total Cash (Recent Filing)$716.10M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)70.4
Beta0.67
Next Earnings
Apr 30, 2026EPS Estimate
1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.55
Shares Outstanding70,395,850
10 Day Avg. Volume1,192,718
30 Day Avg. Volume1,092,729
Financial Highlights & Ratios
PEG Ratio-1.96
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue6.53
Enterprise Value/Gross Profit9.12
Enterprise Value/Ebitda36.36
Forecast
1Y Price Target
$353.47Price Target Upside43.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)6.33
Revenue Forecast (FY)$3.31B
Bulls Say, Bears Say
Bulls Say
Commercial Scale And DistributionPharmacy distribution scale, an expanding prescriber base, and intensified patient sampling programs support deeper market penetration and potential sustained sales momentum.
Product Pipeline And InnovationPlanned next-generation Omnipod devices and a roadmap toward a fully closed-loop system for primary care patients with type 2 diabetes could broaden the addressable market and support future uptake.
Revenue And Customer AdoptionCompany delivered revenue and earnings that beat expectations, driven by strong U.S. adoption and record new customer starts, including a growing share of patients with type 2 diabetes.
Bears Say
Competition And Pricing PressureAdvances from incumbents and new entrants in tubeless and patch pump designs threaten to erode the company's form factor advantage and could introduce pricing pressure.
Moderating Growth OutlookGuidance indicates moderated growth as earlier strong launch comparables are annualized, creating a risk of sales deceleration relative to prior rapid expansion.
Valuation PressureAnalysts lowered price targets to reflect valuation compression across med‑tech peers, which reduces potential upside even if operational performance remains solid.
Insulet News
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $230.05 and its highest was $354.88 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $17.36B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Apr 30, 2026 which is in 59 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Feb 18, 2026. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.468 by $0.082.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.2.
How many shares outstanding does Insulet have?
Insulet has 70,395,850 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.55 in its last earnings report, beating expectations of $1.468. Following the earnings report the stock price went up 4.762%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$353.47 (43.33% Upside)
$353.47 (43.33% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 88.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $257.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.7%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.66%
12-Months-Change
Fundamentals
Return on Equity
18.12%
Trailing 12-Months
Asset Growth
3.33%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Company Deck
PODD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call emphasized strong top-line growth, margin expansion, robust cash generation, broadening commercial reach (notably in type 2 and international markets), and a deep product and clinical pipeline — all supporting continued long-term growth. Near-term headwinds include tougher 2026 comps driving guidance deceleration, higher interest expense from refinancing, elevated capital spending for capacity expansion and some revenue recognition noise. Management presented these headwinds as largely explainable and addressable while reiterating significant investments in R&D, manufacturing and commercial scale to sustain leadership.View all PODD earnings summariesPODD Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
PODD Stock 12 Month Forecast
Average Price Target
$353.47
▲(43.33% Upside)
Technical Analysis
Ownership Overview
0.38% Insiders
38.79% Mutual Funds
19.47% Other Institutional Investors
14.23% Public Companies and Individual Investors